AmerisourceBergen Corporation (ABC)
Last closing price (Nov 25 4:00 EDT):
90.32 (0.31%) ?
AmerisourceBergen Corporation, a pharmaceutical services company, provides drug distribution and related healthcare services and solutions to pharmacy, physician, and manufacturer customers primarily in the United States and Canada. The company distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. It also offers pharmacy automation, inventory management, reimbursement and pharmaceutical consulting, staffing, logistics, and pharmacy management services to healthcare providers and pharmaceutical manufacturers. In addition, the company provides scalable automated pharmacy dispensing equipment, medication and supply dispensing cabinets, and supply management software to various retail and institutional healthcare providers. Further, it offers pharmaceutical distribution and other services to physicians, who specialize in various disease states; distributes plasma and other blood products, injectible pharmaceuticals, and vaccines; and provides third party logistics, reimbursement support programs, outcomes research, contract field staffing, patient and copay assistance, adherence programs, risk mitigation, and other market access programs and services to pharmaceutical and biotechnology manufacturers. Additionally, the company delivers packaging solutions to institutional and retail healthcare providers. It operates through a network of distribution service centers and other operations. AmerisourceBergen Corporation was founded in 1985 and is headquartered in Chesterbrook, Pennsylvania.
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
|Charles Rhyee||Cowen And Company||Buy||Oct 31, '14||85.13||93.00||Oct 31, '15||6.10%|
|John Ransom||Raymond James||Buy||Jul 28, '14||76.91||Jul 28, '15||17.44%|
|Charles Rhyee||Cowen And Company||Buy||Jul 25, '14||76.30||Jul 25, '15||18.37%|
|Charles Rhyee||Cowen And Company||Buy||Apr 25, '14||62.21||Apr 25, '15||45.19%|
|John Ransom||Raymond James||Buy||Apr 25, '14||62.21||Apr 25, '15||45.19%|
|Ross Muken||ISI Group||Buy||Apr 10, '14||64.36||74.00||Apr 10, '15||40.34%|
|David Toung||Argus Research Company||Buy||Jan 24, '14||66.36||83.00||Jan 24, '15||36.11%|
|David Toung||Argus Research Company||Buy||Nov 08, '13||67.09||73.00||Nov 08, '14||29.27%|
|Nicholas Jansen||Raymond James||Buy||Nov 01, '13||65.49||73.00||Nov 01, '14||30.42%|
|Glen Santangelo||Credit Suisse||Buy||Nov 01, '13||65.49||73.00||Nov 01, '14||30.42%|
|Charles Rhyee||Cowen And Company||Buy||Nov 01, '13||65.49||78.00||Nov 01, '14||30.42%|
|Tom Gallucci||Lazard Capital Markets||Buy||Jul 17, '13||57.66||67.00||Jul 17, '14||26.55%|
|Glen Santangelo||Credit Suisse||Buy||Jul 11, '13||57.29||Jul 11, '14||27.28%|
|David Larsen||Leerink Swann Llc||Buy||Jun 11, '13||54.05||Jun 11, '14||33.23%|
|Glen Santangelo||Credit Suisse||Buy||Apr 26, '13||52.50||Apr 26, '14||19.68%|
|Robert Jones||Goldman Sachs||Buy||Apr 10, '13||52.54||Apr 10, '14||23.72%|
|Tom Gallucci||Lazard Capital Markets||Buy||Apr 04, '13||51.08||60.00||Apr 04, '14||28.82%|
|George Hill||Citi||Buy||Mar 20, '13||49.52||Mar 20, '14||35.04%|
|David Toung||Argus Research Company||Buy||Mar 19, '13||49.35||60.00||Mar 19, '14||37.49%|
|Robert Willoughby||BofA Merrill Lynch||Buy||Mar 19, '13||49.35||Mar 19, '14||37.49%|